{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:41:29Z","timestamp":1789749689142,"version":"4.0.1"},"reference-count":59,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Multiple myeloma (<jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>) is the second most common haematological malignancy after non\u2010Hodgkin lymphoma. Despite the improvement in outcomes over the last decade with the introduction of novel therapies, such as immunomodulatory agents (<jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>iDs) and proteasome inhibitors (<jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>s), <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content> remains an incurable disease. Patients who are both refractory to <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>iDs and <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>s carry a particularly dismal prognosis. The development of targeted therapy in the form of monoclonal antibodies has shifted the treatment paradigm of this disease, resulting in unprecedented response rates, even among the highest\u2010risk patients. In this review, we will summarize the mechanism of action and provide an overview of the clinical trials that have led to the <jats:styled-content style=\"fixed-case\">US<\/jats:styled-content> Food and Drug Administration approval of Daratumumab and Elotuzumab, and their current use in the treatment of <jats:styled-content style=\"fixed-case\">MM<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15121","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T02:55:47Z","timestamp":1524711347000},"page":"447-459","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Current use of monoclonal antibodies in the treatment of multiple myeloma"],"prefix":"10.1111","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4882-5581","authenticated-orcid":false,"given":"Cindy","family":"Varga","sequence":"first","affiliation":[{"name":"Tufts Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Maglio","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute Harvard Medical School Jerome Lipper Multiple Myeloma Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"e_1_2_22_2_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V128.22.246.246","article-title":"Evaluation of minimal residual disease (MRD) in relapsed\/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone [abstract]","volume":"128","author":"Avet\u2010Loiseau H.","year":"2016","journal-title":"Blood"},{"issue":"15","key":"e_1_2_22_3_1","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.1200\/jco.2012.30.15_suppl.8087","article-title":"Natural killer (NK) cell activation, cytokine production, and cytotoxicity in human PBMC\/myeloma cell co\u2010culture exposed to elotuzumab (Elo) alone or in combination with lenalidomide (Len)","volume":"30","author":"Balasa B.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_22_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.012"},{"key":"e_1_2_22_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_22_6_1","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1182\/blood.V128.22.3313.3313","article-title":"Daratumumab, bortezomib and dexamethasone versus bortezomib and dexamethasone alone for relapsed or refractory multiple myeloma based on prior treatment exposure: updated efficacy analysis of castor [abstract]","volume":"128","author":"Chanan\u2010Khan A.A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069"},{"key":"e_1_2_22_8_1","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open\u2010label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma [abstract]","volume":"126","author":"Chari A.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_22_9_1","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V128.22.2142.2142","article-title":"Montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma [abstract]","volume":"128","author":"Chari A.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"key":"e_1_2_22_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_22_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00093-X"},{"key":"e_1_2_22_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00217.2004"},{"key":"e_1_2_22_14_1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood.V126.23.28.28","article-title":"Eloquent\u20102 update: a PHASE 3, randomized, open\u2010label study of elotuzumab in combination with lenalidomide\/dexamethasone in patients with relapsed\/refractory multiple myeloma \u2010 3\u2010year safety and efficacy follow\u2010up [abstract]","volume":"126","author":"Dimopoulos M.A.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_22_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_22_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.07.003"},{"key":"e_1_2_22_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.976.976"},{"key":"e_1_2_22_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-414920"},{"key":"e_1_2_22_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13267"},{"key":"e_1_2_22_20_1","unstructured":"Howlader N. Noone A.M. Krapcho M. Garshell J. Miller D. Altekruse S.F. Kosary C.L. Yu M. Ruhl J. Tatalovich Z. Mariotto A. Lewis D.R. Chen H.S. Feuer E.J.&Cronin K.A.(eds). (2014)SEER Cancer Statistics Review 1975\u20132011 National Cancer Institute. Bethesda MD http:\/\/seer.cancer.gov\/csr\/1975_2011\/ based on November 2013 SEER data submission posted to the SEER web site April 2014."},{"key":"e_1_2_22_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"e_1_2_22_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7069"},{"key":"e_1_2_22_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694604"},{"key":"e_1_2_22_24_1","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1182\/blood.V128.22.3437.3437","article-title":"Daratumumab is an effective and safe salvage therapy in relapsed\/refractory patients with multiple myeloma after allogeneic stem cell transplantation","volume":"128","author":"Klyuchnikov E.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_22_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_2_22_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(02)00094-9"},{"key":"e_1_2_22_28_1","doi-asserted-by":"publisher","DOI":"10.1309\/74R4TB90BUWH27JX"},{"issue":"15","key":"e_1_2_22_29_1","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.1200\/jco.2013.31.15_suppl.8512","article-title":"Phase I\/II dose\u2010escalation study of daratumumab in patients with relapsed or refractory multiple myeloma","volume":"31","author":"Lokhorst H. M.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_22_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_2_22_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"e_1_2_22_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_22_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_2_22_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90148-1"},{"key":"e_1_2_22_35_1","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood.V128.22.1150.1150","article-title":"Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor [abstract]","volume":"128","author":"Mateos M.V.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_36_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-1031"},{"key":"e_1_2_22_37_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V128.22.492.492","article-title":"Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients","volume":"128","author":"Nooka A. K.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_38_1","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood.V120.21.1834.1834","article-title":"Daratumumab, a novel human CD38 monoclonal antibody for treatment of multiple myeloma, prevents intra\u2010medullary spreading of patient derived multiple myeloma cells growing in a humanized mouse model [abstract]","volume":"120","author":"Noort W. A.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_22_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13150"},{"key":"e_1_2_22_40_1","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1182\/blood.V128.22.3448.3448","article-title":"Phase 1 study of elotuzumab in combination with autologous stem cell transplantation and lenalidomide maintenance for multiple myeloma","volume":"128","author":"Osman K.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"issue":"15","key":"e_1_2_22_42_1","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/jco.2012.30.15_suppl.8019","article-title":"Daratumumab, a CD38 mab, for the treatment of relapsed\/refractory multiple myeloma patients: preliminary efficacy data from a multicenter phase I\/II study","volume":"30","author":"Plesner T.","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_22_43_1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V126.23.507.507","article-title":"Daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: updated results of a phase 1\/2 study (GEN503)","volume":"126","author":"Plesner T.","year":"2015","journal-title":"Blood"},{"key":"e_1_2_22_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726729"},{"key":"e_1_2_22_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70284-0"},{"key":"e_1_2_22_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2679"},{"key":"e_1_2_22_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862"},{"key":"e_1_2_22_48_1","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood.V122.21.1969.1969","article-title":"MM\u2010005: a Phase 1 trial of pomalidomide, bortezomib, and low\u2010dose dexamethasone (PVD) in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"122","author":"Richardson P.G.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_22_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00197-0"},{"key":"e_1_2_22_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.137"},{"key":"e_1_2_22_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"e_1_2_22_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.62"},{"key":"e_1_2_22_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-705210"},{"key":"e_1_2_22_54_1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood.V128.22.1151.1151","article-title":"Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of pollux [abstract]","volume":"128","author":"Usmani S.Z.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_22_55_1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V128.22.1149.1149","article-title":"Open\u2010label, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO) [abstract]","volume":"128","author":"Usmani S.Z.","year":"2016","journal-title":"Blood"},{"issue":"5","key":"e_1_2_22_56_1","first-page":"v355","article-title":"Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)\u2010based regimens in patients (pts) with multiple myeloma (MM)","volume":"28","author":"Usmani S.Z.","year":"2017","journal-title":"Annals of Oncology"},{"key":"e_1_2_22_57_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030759"},{"key":"e_1_2_22_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-511170"},{"key":"e_1_2_22_59_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003032"},{"key":"e_1_2_22_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:44:59Z","timestamp":1695473099000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/bjh.15121"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15121","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]},"assertion":[{"value":"2018-04-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}